Endoglin is an integral membrane glycoprotein primarily expressed in the vascular endothelium, but also found on macrophages and stromal cells. It binds several members of the transforming growth factor (TGF)-b family of growth factors and modulates TGF-b 1 -dependent cellular responses. However, it lacks cytoplasmic signaling motifs and is considered as an auxiliary receptor for TGF-b. We show here that endoglin is expressed in mouse and human epidermis and in skin appendages, such as hair follicles and sweat glands, as determined by immunohistochemistry. In normal interfollicular epidermis, endoglin was restricted to basal keratinocytes and absent in differentiating cells of suprabasal layers. Follicular expression of endoglin was high in hair bulb keratinocytes, but decreased in parts distal from the bulb. To address the role of endoglin in skin carcinogenesis in vivo, Endoglin heterozygous mice were subjected to long-term chemical carcinogenesis treatment. Reduction in endoglin had a dual effect during multistage carcinogenesis, by inhibiting the early appearance of benign papillomas, but increasing malignant progression to highly undifferentiated carcinomas. Our results are strikingly similar to those previously reported for transgenic mice overexpressing TGF-b 1 in the epidermis. These data suggest that endoglin might attenuate TGF-b 1 signaling in normal epidermis and interfere with progression of skin carcinogenesis.
Introduction
The transforming growth factor-b (TGF-b) plays an important role in epithelial homeostasis, as it modulates the cellular phenotype and is a powerful inhibitor of cell growth (Derynck et al., 2001; Piek and Roberts, 2001) . Members of the TGF-b superfamily exert their biological effects by binding to a heteromeric complex containing two different transmembrane serine/threonine kinases known as type I and type II signaling receptors (Letterio and Roberts, 1998; Massague´, 1998) . The TGF-b receptor complex also contains two auxiliary receptors named endoglin and betaglycan (Massague´, 1998) . These are transmembrane proteins with large extracellular domains and serine/threonine-rich cytoplasmic regions without consensus signaling motifs. Endoglin binds TGF-b 1 , TGF-b 3 , activin-A, BMP-2, and BMP-7 in the presence of the signaling receptors types I and II (Cheifetz et al., 1992; Bello´n et al., 1993; Letamendia et al., 1998a; Barbara et al., 1999) , and modulates TGF-b-dependent cellular responses Letamendia et al., 1998a; Li et al., 2000; Diez-Marques et al., 2002) . Endoglin plays an important role in mammalian physiology as demonstrated by genetic inactivation, since Endoglin null (Eng À/À ) murine embryos die of vascular defects at 10-10.5 days post coitum (Bourdeau et al., 1999; Li et al., 1999; Arthur et al., 2000) . Endoglin is a disulfide-linked homodimer of 180 kDa expressed in endothelial cells (Gougos and Letarte, 1988 Letarte, , 1990 Li et al., 2000) , macrophages (Lastres et al., 1992) , stromal cells (St-Jacques et al., 1994; Robledo et al., 1996) , and other cellular lineages within the vascular system and connective tissues (Fonsatti et al., 2001) . Several tumor cells also express endoglin, including pre-B-cell and monocytic leukemia (Quackenbush and Letarte, 1985; Haruta and Seon, 1986; Lastres et al., 1992; Zhang et al., 1996) , melanoma (Altomonte et al., 1996) , choriocarcinoma (Letamendia et al., 1998b) , and ovarian carcinoma (Jindal et al., 1995) . However, little is known about the possible expression and function of endoglin in epithelial cells.
Approximately 90% of all human tumors are of epithelial origin. TGF-b has both positive and negative effects on carcinogenesis. It behaves as a tumor suppressor, early in tumorigenesis, but can also drive malignant progression, invasion, and metastasis (see Akhurst and Balmain, 1999; Massague´et al., 2000; Derynck et al., 2001 , for reviews). In spite of the large number of studies addressing the role of TGF-b in epithelial carcinogenesis, the specific role played by the TGF-b coreceptor endoglin has not been evaluated in vivo.
The mouse skin model of multistage carcinogenesis has been widely studied and is well characterized with respect to phenotypic and genetic changes (Yuspa, 1994; Akhurst and Balmain, 1999) . Tumor initiation is induced by a single topical application of the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA), and involves a specific oncogenic mutation in the H-Ras gene (Quintanilla et al., 1986) . Thereafter, repeated application of the tumor promoter 12-Otetradecanoylphorbol-13-acetate (TPA) results in the outgrowth of highly differentiated benign papillomas. A small subset of papillomas eventually progresses to malignant squamous cell carcinomas, some of which undergo an epithelial-mesenchymal transition to spindle cell carcinomas (Klein-Szanto et al., 1989; Buchmann et al., 1991) . The spindle cell, the most invasive and motile carcinoma cell type has altered the expression of keratinocyte-specific markers, such as cytokeratins, and show loss of E-cadherin expression (Navarro et al., 1991; Dı´az-Guerra et al., 1992; Frontelo et al., 1998) .
Here, we describe the presence of endoglin in keratinocytes of basal epidermis and hair follicles, the two major cell compartments for tumor initiation in skin carcinogenesis (Akhurst and Balmain, 1999; Taylor et al., 2000) . To investigate the role of endoglin in carcinogenesis, Endoglin heterozygous (Eng þ /À ) mice were subjected to long-term chemical carcinogenesis treatment with DMBA and TPA. We found that endoglin haploinsufficiency had a dual effect during multistage skin carcinogenesis, inhibiting the early appearance of benign tumors, but increasing the late malignant phenotype.
Results

Endoglin is expressed in keratinocytes of normal skin and cutaneous lesions
The presence of endoglin was analysed in human normal skin sections by immunohistochemistry using the specific monoclonal antibody (mAb) SN6h. Endoglin was expressed in the epidermis, restricted exclusively to basal keratinocytes (Figure 1a, b) . The immunostaining pattern was discontinuous in the basal layer with some cells staining weakly or not at all, and in patches in certain regions of the plasma membrane and/or cyto- Endoglin was also present in keratinocytes of hair follicles (Figure 1c) . Intense staining was observed in the hair matrix and in the proximal regions of the outer and inner root sheaths, and decreased in parts distal from the bulb. Mesenchyme-derived dermal papilla fibroblasts were endoglin negative. As seen for interfollicular epidermal cells, hair follicle keratinocytes expressed endoglin in a polarized fashion, with the protein located in certain regions of the plasma membrane and/or cytoplasm in the form of granules or aggregates (Figure 1c, inset) . Basal and ductal cells of the sweat gland were found to express endoglin strongly (Figure 1d ), while high nonspecific staining background was observed in cells of the sebaceous gland (not shown). Immunostaining of normal mouse skin sections with the rat mAb MJ7/18 specific for murine endoglin revealed the same pattern of protein expression in follicular and interfollicular epidermis as in human skin (see below in Figure 6 ).
Since endoglin was present in cells of the epidermis and skin appendages, we analysed its expression in several human cutaneous disorders. To this aim, sections of verruca vulgaris (n ¼ 3), seborrheic keratosis (n ¼ 3), nodular basal cell carcinomas (n ¼ 7), and squamous cell carcinomas (n ¼ 10) were stained with the mAb SN6h. A pattern of staining similar to that of normal epidermis was found in all cases of verruca vulgaris (not shown). In seborrheic keratosis, endoglin staining was extended to proliferating keratinocytes above the basal layer, while absent from terminally differentiating keratinocytes (Figure 2a ). All specimens of nodular basal cell carcinomas were stained with the specific mAb, revealing that endoglin was expressed mainly at the periphery of tumor nests, as dots, on the cell surface in contact with the basement membrane zone. Reduced staining in the inner cell layers was seen in all cases (Figure 2b ). Immunohistochemical analysis of squamous cell carcinomas showed that all tumors expressed endoglin at variable levels regardless of the differentation grade (Figure 2c, d ). Positive staining was observed in the periphery of tumor nests, but not in the central keratinized areas of well-differentiated tumors from which endoglin was excluded ( Figure 2c ).
Endoglin expression in murine keratinocyte cell lines
To characterize endoglin expression in cultured keratinocytes at the mRNA and protein levels, we used a panel of premalignant and malignant mouse epidermal cell lines: PB (papilloma-derived cells), Pam212, HaCa4, and PDV (squamous carcinoma cell lines), and the spindle carcinoma cell lines Car C and Car B. Northern blot experiments with a cDNA probe corresponding to the extracellular domain of the molecule (see Materials and methods) revealed a transcript of 3.1 kb in all the cell lines (Figure 3a ), but detection required a long exposure of the autoradiography indicating a low level This transcript has already been described in other murine tissues such as the ovary, thymus, placenta, and kidney (Ge and Butcher, 1994; St-Jacques et al., 1994; Rodriguez-Pen˜a et al., 2002) . The relative abundance of the endoglin mRNAs among the cell lines was roughly similar, except for PDV carcinoma cells that showed lower levels in this experiment. The presence of endoglin transcripts was confirmed by RT-PCR ( Figure 3b ).
Using specific primers to mouse endoglin, a single 1040-bp PCR product of the predicted size was obtained in all the cell lines tested, including NIH3T3 fibroblasts used as a control. To confirm that this band represented endoglin, it was purified and sequenced, demonstrating its identity with the published murine sequence (Ge and Butcher, 1994; St-Jacques et al., 1994) . Western blots (under reducing conditions) clearly detected a polypeptide of about 95 kDa in PB, HaCa4, and PDV keratinocytes (Figure 3c) . A weaker band was present in Pam212, whereas no specific signal could be detected in Car C and Car B cell lines. Overall, the intensities of the bands detected in the keratinocyte cell lines were low, although comparable to that of NIH3T3 fibroblasts. Parallel blots challenged with preimmune rat IgG, as a negative control, confirmed the specificity of the mAb MJ7/18 (data not shown).
Reduced incidence of chemically induced benign papillomas and enhanced progression to malignant carcinomas in Endoglin heterozygous mice
To analyse the role of endoglin in carcinogenesis, we took advantage of the Eng þ /À mouse that expresses a single endoglin allele on a 129/Ola and C57Bl/6 mixed background (backcrossed onto the C57Bl/6 background for four generations, see Bourdeau et al., 1999) . Two independent skin carcinogenesis experiments were performed using groups of seven (experiment 1) and eight to 10 (experiment 2) male and female mice. Eng þ /À mice and the homozygous littermates (Eng þ / þ ) were treated with an initial dose of DMBA followed twice weekly with TPA for about 20 weeks, as described in Materials and methods. A significant reduction in the number of tumors per mouse and the total yield of tumors was observed in the Eng þ /À versus Eng þ / þ mice throughout the observation period (Figure 4 ). The first appearance of papillomas was noticed on weeks 12 (experiment 1) or 8 (experiment 2) in Eng þ / þ mice and 1-2 weeks later in the corresponding Eng
mice. No significant differences in tumor development were observed between males and females. The histopathological examination of the tumors at the end of the experiments (25 and 23 weeks post-DMBA initiation in experiments 1 and 2, respectively) revealed that all tumors in the Eng þ / þ mice were benign papillomas. However, in the Eng þ /À mice, despite a threefold reduction in the total number of tumors versus the controls, more than half of the developed tumors were malignant carcinomas (Table 1) . Papillomas in the Eng þ /À and Eng þ / þ mice were histologically very similar with abundant keratin and a high level of differentiation (Figure 5a ). Eng þ /À carcinomas showed a variable pattern of differentiation ranging from well-differentiated squamous carcinomas grades I-II (Figure 5b ) to highly undifferentiated carcinomas grades III-IV that showed very little evidence of cellular organization, differentiation, or keratin production (Figure 5d , see also Table 1 ). Carcinomas in the Eng þ /À mice were, in general, very invasive and infiltration into the muscle Strong immunoreactivity was observed in basal and suprabasal keratinocytes (Figure 6c ), but not in differentiating keratinocytes of the upper epidermal layers. Staining was mainly located at the plasma membrane, although some cells also showed an intense intracellular staining. Endoglin expression in suprabasal keratinocytes was preserved in hyperplastic epidermis adjacent to the tumors (not shown). However, in skin distant from the lesions, staining shifted to a pattern similar to that found in the normal epidermis (Figure 6a ), endoglin being restricted to basal-like cells and preferentially intracellular (Figure 6b ). Tumors induced in Eng þ /À mice showed poor immunoreactivity with mAb MJ7/18, although a weak plasma membrane and cytoplasmic staining could be observed in basal and suprabasal keratinocytes of papillomas (Figure 6d ).
These results show that a reduction of endoglin gene dosage inhibits the formation of benign skin tumors, but highly increases the frequency of malignant conversion.
Discussion
So far, most of the research studies on endoglin have focused on its role in angiogenesis and vascular remodeling. This is due to the fact that endoglin is preferentially and strongly expressed in endothelial cells (Gougos and Letarte, 1988; Li et al., 2000) . Furthermore, mutations in the endoglin gene lead to haploinsufficiency and are responsible for the hereditary hemorrhagic telangiectasia type 1 (HHT1), an autosomal dominant disorder characterized by multisystemic vascular dysplasia, and recurrent hemorrhage (Guttmacher et al., 1995; Shovlin and Letarte, 1999; Marchuk and Lux, 2001 ). In addition, endoglin expression is regulated during heart development in human and chicken (Qu et al., 1998; Vincent et al., 1998) ; and endoglin-null mice obtained by targeted disruption of the endoglin gene die at 10-10.5 days post coitum due to vascular and cardiac abnormalities (Bourdeau et al., 1999; Li et al., 1999; Arthur et al., 2000) .
Aside from the endothelial expression of endoglin, several laboratories have reported the presence of endoglin in other cell types, mostly on cellular lineages within the vascular system and connective tissues (see Fonsatti et al., 2001 , for a review). In this work, we show for the first time that endoglin is expressed in the epidermis and skin appendages, such as hair follicles and sweat glands. The presence of endoglin in normal interfollicular epidermis is restricted to keratinocytes of the basal, proliferative, layer, whereas none is detected on suprabasal keratinocytes. This pattern of expression is disrupted in human cutaneous hyperproliferative lesions, such as seborrheic keratosis, and in tumors, such as human basal and squamous cell carcinomas and mouse DMBA/TPA-induced papillomas, where aberrant endoglin expression in suprabasal layers occurs.
To analyse the potential role of endoglin in tumor formation and malignant progression, we used a skin multistage carcinogenesis model in heterozygous C57Bl/ 6 Eng þ /À mice. These mice develop normally, and clinical signs of HHT were present in the 129/Ola strain, but almost absent in the C57Bl/6 strain (Bourdeau et al., 1999 (Bourdeau et al., , 2001 ). None of the Eng þ /À C57Bl/6 mice used in our experiments showed nosebleeds or telangiectases. Our results show that a reduction of Endoglin gene dosage has profound effects on skin neoplasia, affecting both early and late stages of tumorigenesis. Decreased endoglin expression suppresses benign tumor outgrowth, but accelerates malignant conversion and development of highly aggressive poorly differentiated carcinomas, a phenotype first observed in transgenic mice overexpressing TGF-b 1 in the epidermis (Cui et al., 1996) . This study as well as those from other laboratories have led to postulation of a dual role for TGF-b 1 per mouse is plotted versus the number of weeks after initiation with DMBA. In both experiments, reduction in the average tumor number per mouse in Eng þ /À versus Eng þ / þ mice is statistically significant when the tumor numbers reach the plateau. Thus, for example, at weeks 22 and 23 in experiment 1 (P-values o0.05 and o0.01, respectively, using a Student t-test) and at weeks 17 and 18 in experiment 2 (Po0.05 and P ¼ 0.01, respectively) Skin carcinogenesis in Endoglin heterozygous mice M Quintanilla et al in carcinogenesis (Akhurst and Balmain, 1999; Massague´et al., 2000; Derynck et al., 2001; Rich et al., 2001) . TGF-b 1 acts as a suppressor of tumor formation, early in carcinogenesis -by virtue of its well-established antimitogenic function in epithelial cells (Roberts and Sporn, 1990; Alexandrov and Moses, 1995) . At later stages, TGF-b 1 stimulates malignant progression by inducing an epithelial-mesenchymal transition toward an invasive and metastatic phenotype (Caulı´n et al., 1995; Cui et al., 1996; Oft et al., 1996; Frontelo et al., 1998; Portella et al., 1998) , likely in cooperation with oncogenic Ras (Oft et al., 1996 (Oft et al., , 2002 . These TGF-b At the termination of the carcinogenesis experiment (25 weeks post DMBA in experiment 1 and 23 weeks post DMBA in experiment 2), all tumors were enumerated and histologically typed. SCC, squamous cell carcinoma.
effects occur within the tumor cells themselves and require signaling through serine/threonine kinase receptors (Oft et al., 1998; Portella et al., 1998) . Considering this mechanism of action of TGF-b 1 our results strongly suggest that the endoglin level on epithelial keratinocytes is critical for the mediation of TGF-b 1 inhibitory effect since the generation of benign tumors is inhibited in Eng þ /À mice. However, transformation to a more malignant phenotype is observed in these mice, suggesting that normal levels of endoglin would inhibit the effect of TGF-b 1 on malignant progression.
It can be argued, however, that defects in neovascularization could play an additional role in the phenotype observed in our Eng þ /À mice, since endoglin is highly expressed on the tumor-associated angiogenic vascular endothelium (Burrows et al., 1995; Bodey et al., 1998; Kumar et al., 1999; Li et al., 2001; Takahashi et al., 2001) . The importance of angiogenesis for the growth of solid tumors is well recognized (Hanahan and Folkman, 1996) . It has been shown that angiogenesis is a ratelimiting step in the genesis of premalignant lesions such as mouse skin papillomas Larcher et al., 1998) , decreased in Eng þ /À mice in this study. Angiogenesis is also decisive for tumor progression, and halting angiogenesis inhibits development of invasive carcinomas and restores the benign phenotype of malignant keratinocytes (Skobe et al., 1997) . Therefore, it is unlikely that defective angiogenesis would account for the dual phenotype exhibited by Eng þ /À mice during carcinogenesis: decreased tumor formation and accelerated malignant progression. Interestingly, a recent report shows that decreased endoglin expression in cultured human prostate cancer cells enhances cell migration and invasion, while increased expression has opposite effects (Liu et al., 2002) . These findings suggest that the level of endoglin expression can modulate adhesion and motility in transformed epithelial cells, and are in line with the results presented here that reduced endoglin expression in keratinocytes favors progression to invasive carcinomas.
A function for endoglin as an attenuator of TGF-b 1 signaling is supported by our previous studies showing that endoglin inhibits the TGF-b 1 antiproliferative and certain TGF-b 1 -dependent cellular responses Letamendia et al., 1998a; Diez-Marques et al., 2002) . Although the molecular mechanism by which endoglin modulates TGF-b responses remains to be determined, a recent report suggests that by directly et al., 2002) . TGF-b 1 is an endogenous regulator of epidermal homeostasis that is preferentially expressed in suprabasal layers, where it is thought to block proliferation of differentiating keratinocytes (Akhurst et al., 1988; Fowlis et al., 1992; Patamalai et al., 1994) . Interestingly, endoglin is synthesized in basal proliferative keratinocytes, the appropriate cell type to counteract the negative regulation of growth exerted by this factor. Anomalous endoglin expression in suprabasal keratinocytes, as observed in papillomas and carcinomas and other cutaneous hyperplastic disorders, is likely associated with expansion of the proliferative keratinocyte compartment in these lesions (Yuspa, 1994) . Thus, we postulate that the relative levels of endoglin and TGF-b 1 production can mediate the strength of the cellular responses to the growth factor, pointing to endoglin as a potential new target to explore therapeutic strategies to control TGF-b-mediated tumor progression.
Materials and methods
Cell lines and culture
The origin of the mouse epidermal cell lines: Pam212, PB, PDV, HaCa4, Car C, and Car B used in this work has been described (Yuspa et al., 1986; Dı´az-Guerra et al., 1992) . NIH3T3 mouse fibroblast cell line was obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were grown in Ham's F12 medium supplemented with amino acids and vitamins (Pam212, PB, HaCa4, PDV) or Dulbecco's modified Eagle's medium (NIH3T3, Car C, and Car B), with 10% fetal calf serum (Gibco Invitrogen Corp., Barcelona, Spain) and antibiotics (2.5 mg/ml amphotericin B, 100 mg/ml ampicillin, and 32 mg/ml gentamicin; Sigma-Aldrich, Madrid, Spain). Cultures were maintained on plastic at 371C in a 5% CO 2 -humidified atmosphere.
Endoglin heterozygous mice
Endoglin heterozygous (Eng þ /À ) mice were generated by homologous recombination using embryonic stem cells of 129/Ola (129) origin and by backcrossing onto the C57BL/6 (B6) background, as previously described (Bourdeau et al., 1999) . B6-Eng þ /À mice of N4 generation were used in the present studies, as well as their B6-Eng þ / þ littermate controls. Genotypes were determined by PCR analysis of tail DNA isolated using two sets of primers amplifying a 470 bp product in the mutated allele, and a 300 bp product in the wild-type allele (Bourdeau et al., 1999) . Mice were bred and kept in ventilated rooms, in a germ-free facility, under controlled conditions of light, temperature, humidity, food, and water (Rodriguez-Pen˜a et al., 2002 
Chemical carcinogenesis
Tumors were induced on the shaved dorsal skin of 10-week-old mice by a single topical application of 32 mg of DMBA in 200 ml acetone, followed by treatment twice a week with 12.5 mg. of TPA in 200 ml acetone (10 À4 m). The number of tumors (42 mm in diameter) on each mouse was recorded every week. Mice were anesthetized and killed at the end of the experiments, and tumors were fixed in formalin and embedded in paraffin. The tumors were histologically typed by hematoxylin and eosin staining of paraffin sections. Although the pure B6 genetic background is refractory to DMBA/TPA carcinogenesis (Reiners et al., 1984) , the N4 generation of 129 Â B6 mice used in this study yielded four to five tumors per mouse.
Antibodies and immunohistochemical analysis
The human endoglin-specific mAb SN6h (Dako Diagnosticos, Barcelona, Spain) was used for staining formalin-fixed tissues. The mAb MJ7/18 recognizes mouse endoglin (Ge and Butcher, 1994) , and was purchased from BD Biosciences (Heidelberg, Germany). Immunohistochemical detection of endoglin was performed in deparaffinized human and mouse tissue sections by the Envision plus peroxidase method (Dako A/S, Glostrup, Denmark), as previously reported (Velasco et al., 2001) . The reaction product was developed with diaminobenzidine tetrahydrochloride and H 2 O 2 . The sections were dehydrated in graded ethanols, cleared in xylene, and mounted in Permount after counterstaining with hematoxylin.
Northern, RT-PCR, and Western blot analyses
Northern blot hybridization experiments were performed with total RNA extracted from the cell lines by the guanidinium thiocyanate procedure. RNA samples (25 mg) were fractionated on 1% agarose-formaldehyde gels and transferred to Nylon membranes (Schleicher and Schuell, Dassel, Germany). The probe for endoglin mRNA detection was a fragment of 1040 bp generated by RT-PCR from mouse keratinocytes (PB cell line), using oligonucleotides flanking the coding sequence corresponding to the extracellular domain: 5 0 -GTGTGTCTGGTCACAAGGAGGC-3 0 (nucleotides 1001-1022) and 5 0 -GGACAAGGTGCTAGGGCGCAGA-3 0 (nucleotides 2019-2040). PCR conditions were 35 cycles: 951C for 1 min, 631C for 1 min 30 s, 721C for 1 min. For RT-PCR analysis, total RNA samples were incubated with the Moloney murine leukemia virus reverse transcriptase (Promega Corporation, Madison, WI, USA) and the generated cDNAs were used for PCR amplification as described above. PCR products were fractionated in 1% agarose-ethidium bromide gels. The 1040-bp band was isolated using a gel extraction kit (QIAquick; QiagenGmbH, Hilden, Germany) and sequenced in an ABI PRISM 377 machine (PE Applied Biosystems, Foster City, CA, USA).
For detection of endoglin in Western blots, cells were lysed at 41C in buffer RIPA and a cocktail of proteinase inhibitors as previously described (Frontelo et al., 1998) . Aliquots of total cell lysates containing equivalent amounts of protein (30 mg) were separated by 7.5% SDS-PAGE under reducing conditions and electrotransferred to Immobilon P membranes (Millipore Corporation, Bedford, MA, USA) for immunodetection with the rat anti-mouse endoglin mAb MJ7/18 or preimmune rat IgG. As secondary Ab, goat anti-rat IgG coupled to horseradish peroxidase (Pierce, Perbio Science, Bonn, Germany) was used. Filters were reblotted with the anti-a-tubulin mAb DM1A (Sigma Aldrich). The peroxidase activity was developed using an enhanced chemiluminescence kit (Amersham Biosciences).
